ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 Q3 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
ARROWHEAD PHARMACEUTICALS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from maturities of available-for-sale securities → investing reconciliation: $99,634,000.00Proceeds from sales of available-for-sale securities → investing reconciliation: $25,040,000.00investing reconciliation → Net cash from investing activities: $43,683,000.00investing reconciliation → Purchases of available-for-sale securities: $77,137,000.00investing reconciliation → Purchases of property, plant and equipment: $3,854,000.00Proceeds from issuance of common stock - ATM Agreement → financing reconciliation: $27,953,000.00Dividends paid by variable interest entity to noncontrolling shareholders → financing reconciliation: $3,080,000.00Proceeds from the exercises of stock options → financing reconciliation: $2,617,000.00financing reconciliation → Repayments of credit facility: $33,385,000.00financing reconciliation → Payments of issuance costs of common stock - ATM Agreement: $714,000.00Net cash used in operating activities → operating reconciliation: $177,469,000.00Non-cash interest expense on credit facility → operating reconciliation: $15,112,000.00Stock-based compensation → operating reconciliation: $14,872,000.00Non-cash interest expense on liability related to the sale of future royalties → operating reconciliation: $8,683,000.00Accounts receivable → operating reconciliation: $6,954,000.00Accrued expenses → operating reconciliation: $6,922,000.00Depreciation and amortization → operating reconciliation: $6,659,000.00Loss on equity method investment → operating reconciliation: $2,471,000.00Amortization of convertible notes issuance costs → operating reconciliation: $766,000.00Non-cash transfer of property and equipment to affiliate → operating reconciliation: $24,000.00operating reconciliation → Net (loss) income: $178,921,000.00operating reconciliation → Deferred revenue: $30,820,000.00operating reconciliation → Prepaid expenses and other current assets: $21,527,000.00operating reconciliation → Accounts payable: $3,093,000.00operating reconciliation → Other: $2,814,000.00operating reconciliation → Accretion of available-for-sale securities premiums/discounts: $1,607,000.00operating reconciliation → Operating lease, net: $1,133,000.00operating reconciliation → Realized gain on investments: $17,000.00Net cash used in financing activities → financing reconciliation: $449,000.00Difference in the filed cash totals (calculated) → Cash sources and uses: $477,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $188,517,000.00Net cash from investing activities → Cash sources and uses: $43,683,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $54,759,000.00Cash sources and uses → Net cash used in financing activities: $449,000.00Cash sources and uses → Net cash used in operating activities: $177,469,000.00Net (loss) income: -$178,921,000.00Net (loss) income−$178.92 MStock-based compensation: $14,872,000.00Stock-based compensation+$14.87 MDepreciation and amortization: $6,659,000.00Depreciation & amortization+$6.66 MAccretion of available-for-sale securities premiums/discounts: -$1,607,000.00Securities accretion, net−$1.61 MAmortization of convertible notes issuance costs: $766,000.00Debt issuance cost amortization+$766.00 KRealized gain on investments: -$17,000.00Realized investment gain & loss−$17.00 KNon-cash interest expense on liability related to the sale of future royalties: $8,683,000.00Non-cash royalty interest+$8.68 MNon-cash interest expense on credit facility: $15,112,000.00Paid-in-kind interest+$15.11 MLoss on equity method investment: $2,471,000.00Equity-method results+$2.47 MGain on VIE's sale of IPR&D assets: $0.00Non-cash transfer of property and equipment to affiliate: $24,000.00Non-cash PP&E to affiliate+$24.00 KAccounts receivable: $6,954,000.00Accounts receivable+$6.95 MPrepaid expenses and other current assets: -$21,527,000.00Prepaid & other assets−$21.53 MAccounts payable: -$3,093,000.00Accounts payable−$3.09 MAccrued expenses: $6,922,000.00Accrued liabilities+$6.92 MDeferred revenue: -$30,820,000.00Deferred revenue−$30.82 MOperating lease, net: -$1,133,000.00Operating lease liabilities−$1.13 MOther: -$2,814,000.00Other working capital, net−$2.81 MNet cash used in operating activities: -$177,469,000.00. Cash required to fund net payments.Operating cash−$177.47 Moperating reconciliation: $239,932,000.00Proceeds from the exercises of stock options: $2,617,000.00Stock option exercises+$2.62 MProceeds from issuance of warrants: $0.00Proceeds from issuance of convertible notes: $0.00Payments of debt issuance costs: $0.00Purchase of capped calls: $0.00Proceeds from issuance of common stock - ATM Agreement: $27,953,000.00Common stock issued: ATM+$27.95 MProceeds from issuance of common stock - Underwriting Public Offering: $0.00Repayments of credit facility: -$33,385,000.00Long-term credit line repayments−$33.39 MDividends paid by variable interest entity to noncontrolling shareholders: $3,080,000.00Noncontrolling dividends+$3.08 MPayments of issuance costs of common stock - ATM Agreement: -$714,000.00Stock issuance costs: ATM−$714.00 KPayments of issuance costs of common stock - Underwriting Public Offering: $0.00Proceeds from Visirna credit agreement: $0.00Net cash used in financing activities: -$449,000.00. Cash required to fund net payments.Financing cash−$449.00 Kfinancing reconciliation: $34,099,000.00Purchases of property, plant and equipment: -$3,854,000.00PP&E purchases−$3.85 MPurchases of available-for-sale securities: -$77,137,000.00AFS securities purchases−$77.14 MProceeds from sales of available-for-sale securities: $25,040,000.00AFS securities sales+$25.04 MProceeds from maturities of available-for-sale securities: $99,634,000.00AFS securities maturities+$99.63 MNet cash from investing activities: $43,683,000.00Investing cash+$43.68 Minvesting reconciliation: $124,674,000.00Cash sources and uses: $232,677,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $188,517,000.00Beginning cash$188.52 MEnding cash: Cash, cash equivalents, and restricted cash: $54,759,000.00Ending cash$54.76 MDifference in the filed cash totals (calculated): $477,000.00Filer's cash difference(calculated)+$477.00 KCASH RECONCILIATIONInvestingflowsFinancingflowsOperatingflowsNet loss −$178.92M + net operating adjustments $1.45M = operating cash −$177.47MFree cash flow−$181.32 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$133.76 MEnding cash − beginning cash
Chart details

ARROWHEAD PHARMACEUTICALS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
188,517,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 177,469,000 US dollars. Net cash used.
Net (loss) income
negative 178,921,000 US dollars
Stock-based compensation
14,872,000 US dollars
Depreciation and amortization
6,659,000 US dollars
Accretion of available-for-sale securities premiums/discounts
negative 1,607,000 US dollars
Amortization of convertible notes issuance costs
766,000 US dollars
Realized gain on investments
negative 17,000 US dollars
Non-cash interest expense on liability related to the sale of future royalties
8,683,000 US dollars
Non-cash interest expense on credit facility
15,112,000 US dollars
Loss on equity method investment
2,471,000 US dollars
Gain on VIE's sale of IPR&D assets
0 US dollars
Non-cash transfer of property and equipment to affiliate
24,000 US dollars
Accounts receivable
6,954,000 US dollars
Prepaid expenses and other current assets
negative 21,527,000 US dollars
Accounts payable
negative 3,093,000 US dollars
Accrued expenses
6,922,000 US dollars
Deferred revenue
negative 30,820,000 US dollars
Operating lease, net
negative 1,133,000 US dollars
Other
negative 2,814,000 US dollars
Investing activities
43,683,000 US dollars. Net cash provided.
Purchases of property, plant and equipment
negative 3,854,000 US dollars
Purchases of available-for-sale securities
negative 77,137,000 US dollars
Proceeds from sales of available-for-sale securities
25,040,000 US dollars
Proceeds from maturities of available-for-sale securities
99,634,000 US dollars
Financing activities
negative 449,000 US dollars. Net cash used.
Proceeds from the exercises of stock options
2,617,000 US dollars
Proceeds from issuance of warrants
0 US dollars
Proceeds from issuance of convertible notes
0 US dollars
Payments of debt issuance costs
0 US dollars
Purchase of capped calls
0 US dollars
Proceeds from issuance of common stock - ATM Agreement
27,953,000 US dollars
Proceeds from issuance of common stock - Underwriting Public Offering
0 US dollars
Repayments of credit facility
negative 33,385,000 US dollars
Dividends paid by variable interest entity to noncontrolling shareholders
3,080,000 US dollars
Payments of issuance costs of common stock - ATM Agreement
negative 714,000 US dollars
Payments of issuance costs of common stock - Underwriting Public Offering
0 US dollars
Proceeds from Visirna credit agreement
0 US dollars
Operating adjustment reconciliation
239,932,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
34,099,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
124,674,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Difference in the filed cash totals (calculated)
477,000 US dollars. Into cash; drawn as the small gray flow above beginning cash.
Ending cash on Jun 30, 2026
54,759,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
232,677,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 133,758,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 177,469,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
3,854,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 181,323,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$178.92M + net operating adjustments $1.45M = operating cash −$177.47M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Cash-flow net income is −$178.92 M, derived by subtracting the earlier cumulative period; the income statement reports −$178.92 M for the same period. The difference is −$5.00 K. Neither amount has been adjusted.
  • The filer's reported cash figures differ by $477.00 K: its ending cash less its beginning cash does not equal its reported net change in cash. The chart shows the difference as its own calculated flow; no reported amount has been adjusted.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 177,469,000 US dollars minus 3,854,000 US dollars equals negative 181,323,000 US dollars.
  • Cash-flow net income is −$178.92 M, derived by subtracting the earlier cumulative period; the income statement reports −$178.92 M for the same period. The difference is −$5.00 K. Neither amount has been adjusted.
  • The filer's reported cash figures differ by $477.00 K: its ending cash less its beginning cash does not equal its reported net change in cash. The chart shows the difference as its own calculated flow; no reported amount has been adjusted.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!